RESUMEN
BACKGROUND: Fair financial contribution in healthcare financing is one of the main goals and challengeable subjects in the evaluation of world health system functions. This study aimed to investigate the equity in healthcare financing in Shiraz, Iran in 2018. MATERIALS AND METHODS: This was a cross- sectional survey conducted on the Shiraz, Iran households. A sample of 740 households (2357 persons) was selected from 11 municipal districts using the multi-stage sampling method (stratified sampling method proportional to size, cluster sampling and systematic random sampling methods). The required data were collected using the Persian format of "World Health Survey" questionnaire. The collected data were analyzed using Stata14.0 and Excel 2007. The Gini coefficient and concentration and Kakwani indices were calculated for health insurance premiums (basic and complementary), inpatient and outpatient services costs, out of pocket payments and, totally, health expenses. RESULTS: The Gini coefficient was obtained based on the studied population incomes equal to 0.297. Also, the results revealed that the concentration index and Kakwani index were, respectively, 0.171 and - 0.125 for basic health insurance premiums, 0.259 and - 0.038 for health insurance complementary premiums, 0.198 and - 0.099 for total health insurance premiums, 0.126 and - 0.170 for outpatient services costs, 0.236 and - 0.061 for inpatient services costs, 0.174 and - 0.123 for out of pocket payments (including the sum of costs related to the inpatient and outpatient services) and 0.185 and - 0.112 for the health expenses (including the sum of out of pocket payments and health insurance premiums). CONCLUSION: The results showed that the healthcare financing in Shiraz, Iran was regressive and there was vertical inequity and, accordingly, it is essential to making more efforts in order to implement universal insurance coverage, redistribute incomes in the health sector to support low-income people, strengthening the health insurance schemes, etc.
Asunto(s)
Gastos en Salud/ética , Gastos en Salud/estadística & datos numéricos , Financiación de la Atención de la Salud/ética , Cobertura del Seguro/ética , Seguro de Salud/ética , Cobertura Universal del Seguro de Salud/ética , Cobertura Universal del Seguro de Salud/estadística & datos numéricos , Estudios Transversales , Femenino , Humanos , Cobertura del Seguro/estadística & datos numéricos , Seguro de Salud/estadística & datos numéricos , Irán , MasculinoRESUMEN
Since the adoption of the law of March 6, 2017, any German physician can prescribe medical cannabis flowers and cannabis-based magistral and finished medicinal products. No specific indications for prescriptions are provided in the law. The statutory health insurance companies bear the costs once an application for cost coverage has been approved by the Medical Service of the Health Funds. The German associations of psychiatry (child, adolescents, and adults), neurology, palliative care, addictology, and pain medicine are watching these developments in the media, politics, and medical world with concern due to: the option to prescribe cannabis flowers despite the lack of sound evidence and against the recommendations of the German Medical Association; the lack of distinction between medical cannabis flowers and cannabis-based magistral and finished medical products; the indiscriminately positive reports on the efficacy of cannabis-based medicines for chronic pain and mental disorders; the attempts by the cannabis industry to influence physicians; the increase in potential indications by leaders of medical opinion paid by manufacturers of cannabis-based medicines. The medical associations make the following appeal to journalists: To report on the medical benefits and risks of cannabis-based medicines in a balanced manner. To physicians: to prescribe cannabis-based medicines with caution; to prefer magistral and finished medicinal products over cannabis flowers. To politicians: to consider data according to the standards of evidence-based medicine when making decisions and provide financial support for medical research into cannabis-based medicines.
Asunto(s)
Cannabis , Dolor Crónico , Seguro de Salud , Periodismo , Marihuana Medicinal , Política , Pautas de la Práctica en Medicina , Dolor Crónico/tratamiento farmacológico , Alemania , Humanos , Seguro de Salud/ética , Seguro de Salud/normas , Marihuana Medicinal/uso terapéutico , Médicos/ética , Médicos/normas , Pautas de la Práctica en Medicina/ética , Pautas de la Práctica en Medicina/normasRESUMEN
While citizens in a liberal democracy are generally expected to see to their basic needs out of their own income shares, health care is treated differently. Most rich liberal democracies provide their citizens with health care or health care insurance in kind. Is this "special" treatment justified? The predominant liberal account of justice in health care holds that the moral importance of health justifies treating health care as special in this way. I reject this approach and offer an alternative account. Health needs are not more important than other basic needs, but they are more unpredictable. I argue that citizens are owed access to insurance against health risks to provide stability in their future expectations and thus to protect their capacities for self-determination.
Asunto(s)
Accesibilidad a los Servicios de Salud/ética , Seguro de Salud/ética , Derechos Humanos , Humanos , Formulación de PolíticasRESUMEN
Priority setting is inevitable on the path towards universal health coverage. All countries experience a gap between their population's health needs and what is economically feasible for governments to provide. Can priority setting ever be fair and ethically acceptable? Fairness requires that unmet health needs be addressed, but in a fair order. Three criteria for priority setting are widely accepted among ethicists: cost-effectiveness, priority to the worse-off, and financial risk protection. Thus, a fair health system will expand coverage for cost-effective services and give extra priority to those benefiting the worse-off, whilst at the same time providing high financial risk protection. It is considered unacceptable to treat people differently according to their gender, race, ethnicity, religion, sexual orientation, social status, or place of residence. Inequalities in health outcomes associated with such personal characteristics are therefore unfair and should be minimized. This commentary also discusses a third group of contested criteria, including rare diseases, small health benefits, age, and personal responsibility for health, subsequently rejecting them. In conclusion, countries need to agree on criteria and establish transparent and fair priority setting processes.
Asunto(s)
Prioridades en Salud , Administración de los Servicios de Salud , Seguro de Salud , Cobertura Universal del Seguro de Salud/ética , Análisis Costo-Beneficio , Femenino , Administración de los Servicios de Salud/economía , Administración de los Servicios de Salud/ética , Humanos , Seguro de Salud/economía , Seguro de Salud/ética , Masculino , Principios Morales , Factores SocioeconómicosRESUMEN
Dr F. Inest practices surgery at a renowned medical center but is concerned because increasing numbers of medical insurers are excluding his institution from coverage. Many of his former referring physicians are beginning to send their patients elsewhere for this reason. The marketing people have been busy increasing their advertising buys and exploring new business models. There is even talk about reducing expensive clinical trials. However, regardless of his affiliation, he has little control over these and other organizational decisions that directly impact his practice clinically and fiscally. What should he do?
Asunto(s)
Centros Médicos Académicos/economía , Atención a la Salud/economía , Costos de la Atención en Salud , Accesibilidad a los Servicios de Salud/economía , Cobertura del Seguro/economía , Reembolso de Seguro de Salud/economía , Seguro de Salud/economía , Derivación y Consulta/economía , Centros Médicos Académicos/ética , Publicidad/economía , Conflicto de Intereses/economía , Atención a la Salud/ética , Costos de la Atención en Salud/ética , Accesibilidad a los Servicios de Salud/ética , Humanos , Cobertura del Seguro/ética , Seguro de Salud/ética , Reembolso de Seguro de Salud/ética , Comercialización de los Servicios de Salud/economía , Derivación y Consulta/éticaAsunto(s)
Reforma de la Atención de Salud/legislación & jurisprudencia , Seguro de Salud/legislación & jurisprudencia , Patient Protection and Affordable Care Act , Política , Cobertura del Seguro/tendencias , Seguro de Salud/economía , Seguro de Salud/ética , Patient Protection and Affordable Care Act/economía , Estados UnidosAsunto(s)
Técnicas Reproductivas , Justicia Social , Brasil/epidemiología , Epidemias , Femenino , Accesibilidad a los Servicios de Salud/economía , Accesibilidad a los Servicios de Salud/ética , Accesibilidad a los Servicios de Salud/legislación & jurisprudencia , Disparidades en el Estado de Salud , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Recién Nacido , Seguro de Salud/economía , Seguro de Salud/ética , Seguro de Salud/legislación & jurisprudencia , Legislación como Asunto/tendencias , Masculino , Embarazo , Técnicas Reproductivas/economía , Técnicas Reproductivas/ética , Técnicas Reproductivas/legislación & jurisprudencia , Factores de Riesgo , Justicia Social/ética , Justicia Social/legislación & jurisprudencia , Justicia Social/tendencias , Factores SocioeconómicosRESUMEN
BACKGROUND: Section 114 of the Food and Drug Administration Modernization Act of 1997 regulates the promotion of health economic information by pharmaceutical companies to US health plans. Greater clarity is important given demands by payers and other stakeholders for evidence of value. OBJECTIVES: To develop hypothetical case studies of health economic promotions to examine legal and policy implications. METHODS: We constructed for pedagogical purposes 10 categories of potential health economic promotions. We generated hypothetical case studies for each category, including questions about whether each might be allowable under Section 114. The case studies were developed around the following categories: 1) costing out on-label clinical end points; 2) promotion of a costing exercise to physicians working in an accountable care organization setting; 3) burden-of-illness claims; 4) economic analysis of a formulary restriction policy; 5) extrapolations to doses, populations, or settings not covered in trials; 6) adherence claims; 7) "utilization of care" as a secondary end point in randomized clinical trials; 8) costing out a competitor drug's adverse event; 9) economic analysis of comparative effectiveness claims using an indirect treatment comparison; and 10) extrapolating from surrogate to long-term outcomes in an economic model. DISCUSSION: Most cases seem to fall into a gray zone given haziness around what constitutes "competent and reliable evidence" and "directly relate[d]" to an approved indication. In practice, it is difficult to know what the section allows given the imprecision of the statute and lack of guidance about its scope. CONCLUSION: Ideally, future guidance will provide clarity and flexibility.
Asunto(s)
Publicidad/legislación & jurisprudencia , Industria Farmacéutica/legislación & jurisprudencia , Sistemas de Información en Salud/legislación & jurisprudencia , Política de Salud/legislación & jurisprudencia , Seguro de Salud/legislación & jurisprudencia , Comercialización de los Servicios de Salud/legislación & jurisprudencia , United States Food and Drug Administration/legislación & jurisprudencia , Publicidad/economía , Publicidad/ética , Investigación sobre la Eficacia Comparativa/legislación & jurisprudencia , Conflicto de Intereses , Ahorro de Costo , Análisis Costo-Beneficio , Costos de los Medicamentos/legislación & jurisprudencia , Industria Farmacéutica/economía , Industria Farmacéutica/ética , Medicina Basada en la Evidencia/legislación & jurisprudencia , Formularios Farmacéuticos como Asunto , Sistemas de Información en Salud/economía , Sistemas de Información en Salud/ética , Política de Salud/economía , Humanos , Seguro de Salud/economía , Seguro de Salud/ética , Relaciones Interinstitucionales , Comercialización de los Servicios de Salud/economía , Comercialización de los Servicios de Salud/ética , Años de Vida Ajustados por Calidad de Vida , Revelación de la Verdad , Estados Unidos , United States Food and Drug Administration/economía , United States Food and Drug Administration/éticaRESUMEN
This paper presents an analysis of the effect of globalisation and attendant economic factors on the global practice of medicine, medical education, medical ethics and medical professionalism. The authors discuss the implications of these trends, citing case scenarios in the healthcare insurance, medical tourism, pharmaceutical industries, and the educational systems as well as in clinical practice, to illustrate the impact of globalisation and economics on professionalism. Globalisation, on the one hand, offers benefits for the global practice of medicine and for medical education. On the other, globalisation can have negative effects, particularly when the main driver is to maximise profitability across national boundaries rather than concern for human well-being. Appraising the effect of globalisation on professionalism involves assessing its effects at the intrapersonal, interpersonal, and institutional levels, and its effect on society at large.
Asunto(s)
Educación Médica/ética , Internacionalidad , Profesionalismo/ética , Industria Farmacéutica/ética , Humanos , Seguro de Salud/ética , Turismo Médico/éticaRESUMEN
Social, technical and legal conditions of the current practice of medicine make it necessary to insist on certain actions and circumstances that may jeopardize the confidentiality of information, offered by patients to their health providers. Therefore, some effects of the current Chilean law are analyzed in this respect, regarding access to data from the clinical record of a patient. Also, the risks of putting certain data on social networking sites are analyzed, as well as some of its effects on clinical practice. The reasons because of mandatory reporting of diseases, meaning danger to public health, is allowed, are mentioned. We also discuss the difficulties involved in managing the results of preventative health screenings and its knowledge by third parties, as well as some possible violations of personal privacy, regarding dissemination of some people health information and its further mention or figuration in mass media. We conclude that it is a must for both physicians and other health team members, to safeguard confidentiality of data to which they have had access, as well as the need to know the relevant law, in order to respect human dignity of patients, each one as a person. We address the attention to the possibility that, practicing in a different way, it could endanger the reliability of clinical records, also impairing the quality of people's health care.
Asunto(s)
Confidencialidad/legislación & jurisprudencia , Registros Médicos , Acceso a la Información/ética , Acceso a la Información/legislación & jurisprudencia , Chile , Confidencialidad/ética , Notificación de Enfermedades , Humanos , Difusión de la Información/ética , Seguro de Salud/ética , Registros Médicos/legislación & jurisprudencia , Registros Médicos/normas , Acceso de los Pacientes a los Registros/legislación & jurisprudencia , Derechos del Paciente/legislación & jurisprudencia , Personeidad , Red SocialRESUMEN
This article examines privacy threats arising from the use of data mining by private Australian health insurance companies. Qualitative interviews were conducted with key experts, and Australian governmental and nongovernmental websites relevant to private health insurance were searched. Using Rationale, a critical thinking tool, the themes and considerations elicited through this empirical approach were developed into an argument about the use of data mining by private health insurance companies. The argument is followed by an ethical analysis guided by classical philosophical theories-utilitarianism, Mill's harm principle, Kant's deontological theory, and Helen Nissenbaum's contextual integrity framework. Both the argument and the ethical analysis find the use of data mining by private health insurance companies in Australia to be unethical. Although private health insurance companies in Australia cannot use data mining for risk rating to cherry-pick customers and cannot use customers' personal information for unintended purposes, this article nonetheless concludes that the secondary use of customers' personal information and the absence of customers' consent still suggest that the use of data mining by private health insurance companies is wrong.
Asunto(s)
Minería de Datos/ética , Seguro de Salud/ética , Privacidad , Sector Privado/ética , Australia , Humanos , Filosofía MédicaRESUMEN
On 26 February 2013 the new "Law on Patients' Rights" (hereinafter also the "Law") became effective. This Law strengthens patients' rights vis-à-vis the insurdnce company and also regulates patients' rights regarding their relation to the doctor. This has consequences for the laws on medical liability all doctors must consider. The doctor's performance is and remains a service and such service does not hold any guarantee of success. Nevertheless, this Law primarily reads as a "law on the duties of physicians". To duly take into account these duties and to avoid mistakes and misinterpretation of the Law, the Ethics Committee of the Consortium of Osteosynthesis Trauma Germany (AOTRAUMA-D) has drafted comments on the Law. Brief summaries of its effects are to be found at the end of the respective comment under the heading "Consequences for Practice". The text of the law was influenced particularly by case law, as continuously developed by the German Federal Court of Justice ("BGH"). The implementation of the Law on Patients' Rights was effected by the newly inserted sections 630a to 630h of the German Civil Code (the "BGB"), which are analysed below. The following comments are addressed to physicians only and do not deal with the specific requirements and particularities of the other medical professions such as physiotherapy, midwifery and others so on. Special attention should be paid to the comments on the newly inserted Duty to inform, which has to be fullfilled prior to any diagnostic or therapeutic procedure (sec. 630c para 2 sentence 1 BGB). Under certain conditions the doctor also has to inform the patient about the circumstances that lead to the presumed occurance of a therapeutic or diagnostic malpractice (sec. 630c para. 2 sentence 2 BGB), based on the manifestation of an undesired event or an undesired outcome. As before, the patient's valid consent to any procedure (sec. 630d BGB) is directly linked to the comprehensive and timely provision of information (sec. 630e BGB). Comprehensive documentation obligations regarding all procedures are stipulated in sec. 630f BGB. As before, the burden of proof still rests with the patient, unless a severe malpractice has been established (sec. 630h BGB). The definition of "severe malpractice" remains unchanged and is based on the case law of the Federal Court of Justice (BGH). The patient's obligations to preserve his or her health and to actively support the process of recovery and securing a positive outcome of the treatment are not explicitly mentioned in the Law. Nevertheless, the patient and the physician need to work closely together to achieve a successful result of the treatment. In case the patient does not give his or her cooperation, the physician should consider terminating the treatment relationship.
Asunto(s)
Seguro de Salud/ética , Seguro de Salud/legislación & jurisprudencia , Programas Nacionales de Salud/ética , Programas Nacionales de Salud/legislación & jurisprudencia , Derechos del Paciente/ética , Derechos del Paciente/legislación & jurisprudencia , Relaciones Médico-Paciente/ética , Ética Médica , Alemania , Humanos , Consentimiento Informado/ética , Consentimiento Informado/legislación & jurisprudencia , Mala Praxis/legislación & jurisprudencia , Educación del Paciente como Asunto/ética , Educación del Paciente como Asunto/legislación & jurisprudenciaRESUMEN
Point-of-care evidence-based medicine websites allow physicians to answer clinical queries using recent evidence at the bedside. Despite significant research into the function, usability and effectiveness of these programmes, little attention has been paid to their ethical issues. As many of these sites summarise the literature and provide recommendations, we sought to assess the role of conflicts of interest in two widely used websites: UpToDate and Dynamed. We recorded all conflicts of interest for six articles detailing treatment for the following conditions: erectile dysfunction, fibromyalgia, hypogonadism, psoriasis, rheumatoid arthritis and Crohn's disease. These diseases were chosen as their medical management is either controversial, or they are treated using biological drugs which are mostly available by brand name only. Thus, we hypothesised that the role of conflict of interest would be more significant in these conditions than in an illness treated with generic medications or by strict guidelines. All articles from the UpToDate articles demonstrated a conflict of interest. At times, the editor and author would have a financial relationship with a company whose drug was mentioned within the article. This is in contrast with articles on the Dynamed website, in which no author or editor had a documented conflict. We offer recommendations regarding the role of conflict of interest disclosure in these point-of-care evidence-based medicine websites.
Asunto(s)
Conflicto de Intereses , Sistemas de Apoyo a Decisiones Clínicas/ética , Industria Farmacéutica/ética , Seguro de Salud/ética , Internet/ética , Sistemas de Atención de Punto/ética , Pautas de la Práctica en Medicina/ética , Artritis Reumatoide/tratamiento farmacológico , Enfermedad de Crohn/tratamiento farmacológico , Disfunción Eréctil/tratamiento farmacológico , Medicina Basada en la Evidencia , Fibromialgia/tratamiento farmacológico , Humanos , Hipogonadismo/tratamiento farmacológico , Masculino , Psoriasis/tratamiento farmacológico , Calidad de la Atención de Salud , Estados UnidosRESUMEN
In the employer-sponsored insurance market that covers most Americans; many workers are "underinsured." The evidence shows onerous out-of-pocket payments causing them to forgo needed care, miss work, and fall into bankruptcies and foreclosures. Nonetheless, many higher-paid workers are "overinsured": the evidence shows that in this domain, surplus insurance stimulates spending and price inflation without improving health. Employers can solve these problems together by scaling cost-sharing to wages. This reform would make insurance better protect against risk and guarantee access to care, while maintaining or even reducing insurance premiums. Yet, there are legal obstacles to scaled cost-sharing. The group-based nature of employer health insurance, reinforced by federal law, makes it difficult for scaling to be achieved through individual choices. The Affordable Care Act's (ACA) "essential coverage" mandate also caps cost-sharing even for wealthy workers that need no such cap. Additionally, there is a tax distortion in favor of highly paid workers purchasing healthcare through insurance rather than out-of-pocket. These problems are all surmountable. In particular, the ACA has expanded the applicability of an unenforced employee-benefits rule that prohibits "discrimination" in favor of highly compensated workers. A novel analysis shows that this statute gives the Internal Revenue Service the authority to require scaling and to thereby eliminate the current inequities and inefficiencies caused by the tax distortion. The promise is smarter insurance for over 150 million Americans.
Asunto(s)
Seguro de Costos Compartidos/métodos , Planes de Asistencia Médica para Empleados/economía , Gastos en Salud/normas , Seguro de Salud/economía , Salarios y Beneficios , Seguro de Costos Compartidos/ética , Planes de Asistencia Médica para Empleados/ética , Reforma de la Atención de Salud , Humanos , Seguro de Salud/ética , Patient Protection and Affordable Care Act , Impuestos/economía , Estados UnidosRESUMEN
In this article we describe the successes of Aetna's Compassionate Care Program in providing case management services for people with advanced illnesses.
Asunto(s)
Toma de Decisiones/ética , Empatía , Seguro de Salud , Cuidado Terminal , Conflicto de Intereses , Humanos , Cobertura del Seguro/ética , Cobertura del Seguro/organización & administración , Cobertura del Seguro/tendencias , Seguro de Salud/ética , Seguro de Salud/organización & administración , Seguro de Salud/tendencias , Medicare , Desarrollo de Programa , Evaluación de Programas y Proyectos de Salud , Cuidado Terminal/economía , Cuidado Terminal/métodos , Estados UnidosRESUMEN
It is important to recognize the political and policy accomplishments of the Patient Protection and Affordable Care Act (ACA), anticipate its limitations, and use the levers it provides strategically to address the problems it does not resolve. Passage of the ACA broke the political logjam that long stymied national progress toward equitable, quality, universal, affordable health care. It extends coverage for the uninsured who are disproportionately low income and people of color, curbs health insurance abuses, and initiates improvements in the quality of care. However, challenges to affordability and cost control persist. Public health advocates should mobilize for coverage for abortion care and for immigrants, encourage public-sector involvement in negotiating health care prices, and counter disinformation by opponents on the right.
Asunto(s)
Política de Salud/legislación & jurisprudencia , Seguro de Salud/ética , Patient Protection and Affordable Care Act/legislación & jurisprudencia , Humanos , Seguro de Salud/economía , Patient Protection and Affordable Care Act/economía , Estados UnidosRESUMEN
A response to Anne Haehl's commentary, "Fertility Treatment: Medically Necessary?"
Asunto(s)
Infertilidad/economía , Cobertura del Seguro/ética , Seguro de Salud/ética , Técnicas Reproductivas Asistidas/economía , Técnicas Reproductivas Asistidas/ética , Femenino , Humanos , MasculinoRESUMEN
This article offers two revisions to Dworkin's 'prudent insurance ideal', which aims to account for justice in the distribution of healthcare so that (a) it can deal with market failures in healthcare and (b) when applied to unjust societies it addresses health problems caused by injustice in a fair manner.
Asunto(s)
Toma de Decisiones/ética , Atención a la Salud/ética , Seguro de Salud/ética , Altruismo , Humanos , Modelos Psicológicos , Política Pública , Asignación de Recursos/ética , Justicia Social , Factores SocioeconómicosRESUMEN
BACKGROUND/AIMS: To assess awareness of genetic testing for breast cancer risk and identify influences on the decision-making process regarding counseling and testing among an ethnically-diverse sample of women. METHODS: Semi-structured interviews were conducted with 33 women who were breast or ovarian cancer survivors or first degree relatives of survivors. Interviews were audiotaped, translated, and transcribed. Analysis of transcripts identified relevant themes and quotes were extracted for illustration. RESULTS: Low levels of awareness were observed in minority women, including those with a significant family history of cancer. A number of potential influences on the decision-making process emerged including beliefs about risk factors for cancer and opinions about the options following testing. Distinct issues were identified within ethnic groups that may function as barriers such as concern about the misuse of genetic information (African Americans), unfamiliarity with Western preventive medicine (Asians), and women prioritizing family obligations over personal health needs (Latinas). CONCLUSIONS: Results suggest there may be a need for interventions to raise awareness about genetic counseling and testing among minorities. Our findings contribute to the literature by using in-depth interviews to uncover potential barriers and facilitators to counseling and testing and by including Asians and Latinas, groups under-represented in previous research.
Asunto(s)
Neoplasias de la Mama/genética , Pruebas Genéticas , Conocimientos, Actitudes y Práctica en Salud/etnología , Seguro de Salud , Prejuicio , Negro o Afroamericano , Pueblo Asiatico , Toma de Decisiones , Femenino , Privacidad Genética , Hispánicos o Latinos , Humanos , Seguro de Salud/ética , Entrevistas como Asunto , Persona de Mediana Edad , Neoplasias Ováricas/genética , Percepción , Factores de RiesgoRESUMEN
A growing number of discharges at acute-care hospitals involve patients who are undocumented and lack legal status. Because such patients are ineligible for public assistance, long-term care facilities will routinely deny them admission. These discharges become complex discharges because of such financial barriers. If local family support is unavailable, discharging such patients to a safe and suitable location becomes increasingly difficult. These complex discharges implicate a number of ethical principles. We describe such complex discharge cases, apply various ethical frameworks, and call for potential policy solutions to address this growing ethical concern.